The observed effects were associated with the ability of PDA-NPs to efficiently target the transmembrane MUC18 marker highly expressed in metastatic cancers and subsequently alter cytoskeletal actin dynamics, as well as cell morphology and stiffness (Liu et al., 2021). Here, MCAM is linked to metastatic malignant neoplasm.